arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

HAEMONETICS CORP

HAE
$87.83 ▲ +2.82 (+3.32%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
70 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bearish
auto_awesome

Analytical Summary

HAEMONETICS CORP faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 4.8%
Op. Margin -6.6%
ROIC -0.8%
FCF / Share None
Trailing P/E
Price / Book 5.0x
FCF Yield
Debt / Equity 1.56
info Valuation on last close. End-of-day price, Aug 7, 2026.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$346.35M
↑ +4.8%
Net Income Profit after all expenses
$-20.15M
↓ -159.2%
Operating Margin Operating profit as % of sales
-6.6%
↓ -133.4% 73th
FCF / Share Free cash flow per share
$1.86
↓ -16.6%
Long-Term Debt Long-term obligations
$1.24B
↑ +1.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
71
Returns
67
Financial Health
48
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 70 quarters